Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Docetaxel
Related studies linked through entity extraction aliases.
Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
- Status
- COMPLETED
- Phase
- N/A
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- NA
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE3
A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
- Status
- RECRUITING
- Phase
- PHASE2
Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
- Status
- TERMINATED
- Phase
- PHASE2
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
- Status
- COMPLETED
- Phase
- PHASE3
Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
- Status
- TERMINATED
- Phase
- PHASE1
Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2